Foundation Executive Vice President for Medical Affairs Quoted in NY Times
| 1 min read

A story this week in the New York Times discusses the need for an alternative to pig-derived pancreatic enzyme supplements for cystic fibrosis patients. It highlights the Foundation's collaboration with Altus Pharmaceuticals to develop a synthetic, non-animal derived product.

Preston W. Campbell, III, M.D., executive vice president for medical affairs of the Cystic Fibrosis Foundation, says in the article that if a problem developed in the pig population and resulted in a recall of enzymes, it could be a serious health threat for  people with CF. That's why the Foundation is proactively pursuing a synthetic alternative, he said.

Read the full story.

Share this article
Topics
About the CF Foundation | Medications | Drug Pipeline
Recent news
CF Foundation Awards Advance Improvements in CF Newborn Screening
News | 4 min read
Cystic Fibrosis Foundation Awards 2023 Impact Grants
News | 5 min read
Adult with CF Provides Testimony at Congressional Hearing on the Impact of Antimicrobial Resistance 
News | 3 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe